Shedding a light on why children with high-risk neuroblastoma don’t respond to current therapies
Hamid Maadi’s new research project is working to increase the efficacy of current cancer treatment strategies.
Hamid Maadi is looking to shed light on why children with a deadly type of cancer that affects developing nerve tissue don’t respond well to current treatments like radiation and chemotherapies.
Neuroblastoma makes up six per cent of all childhood cancers and is responsible for 15 per cent of pediatric cancer deaths. Up to 60 per cent of children diagnosed with high-risk neuroblastoma don’t survive past the age of five.
Maadi, a postdoctoral fellow supervised by Roseline Godbout in the Department of Oncology, explained that increased copies of two genes are associated with poor patient prognosis.